VA Consolidation in Intermediate-Risk AML

Inclusion Criteria: * Confirmed diagnosis of acute myeloid leukemia (AML) according to WHO 2022 classification criteria; * Age ≥ 18 years; * Classified as intermediate-risk based on European LeukemiaNet (ELN) 2022 prognostic risk stratification; * Achieved first complete remission (CR) or CR with incomplete hematologic recovery (CRi) after ≤ 2 cycles of Venetoclax + Azacitidine (VA) induction therapy; * Has a suitable donor and is planned to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT); * ECOG performance status score 0 to 2 * Adequate organ function: creatinine clearance ≥ 50 mL/min; AST and ALT ≤ 3 × ULN; total bilirubin ≤ 2 × ULN; LVEF ≥ 50%; life expectancy \> 8 weeks * Voluntarily signed informed consent form and able to comply with study requirements Exclusion Criteria: * Clinically active cardiovascular disease (uncontrolled arrhythmia/hypertension, NYHA Class 3/4 heart failure, myocardial infarction within 3 months) * Active central nervous system (CNS) leukemia or extramedullary infiltration * Other serious diseases limiting participation (e.g., severe infection, renal failure) * Known HIV infection or uncontrolled severe viral hepatitis * Pregnant or breastfeeding women * Inability to understand, comply with protocol, or sign informed consent * Any other conditions deemed unsuitable by the investigator